Please Note: This trial is no longer enrolling new participants
A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib, Trastuzumab, with or without Endocrine Therapy for 12 weeks vs. 24 weeks in patients with HER2 Overexpressing Breast Cancer
| Protocol No. | TBCRC023 | Scope | National |
|---|---|---|---|
| Principal Investigator | Kathy Miller | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
